ESTRO 2025 - Abstract Book

S1289

Clinical - Lung

ESTRO 2025

References: Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. The New England journal of medicine. 2017;377(20):1919-29. Naidoo J, Vansteenkiste JF, Faivre-Finn C, Özgüroğlu M, Murakami S, Hui R, et al. Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial. Lung cancer (Amsterdam, Netherlands). 2022;166:84-93. Suresh K, Voong KR, Shankar B, Forde PM, Ettinger DS, Marrone KA, et al. Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors. Journal of thoracic oncology . 2018;13(12):1930-9.

109

Digital Poster Impact of duration of consolidation durvalumab after definitive chemoradiotherapy and EGFR status on outcomes in locally advanced NSCLC Hiroshi Doi, Junki Fukuda, Naoko Ishida, Saori Tatsuno, Takuya Uehara, Masahiro Inada, Kiyoshi Nakamatsu, Makoto Hosono, Yukinori Matsuo Department of Radiation Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan Purpose/Objective: We have recently reported that consolidation durvalumab should be administered for more than 6 months to achieve the primary benefit of consolidation therapy after definitive chemoradiotherapy (dCRT) for locally advanced non-small cell lung cancer (LA-NSCLC) [1]. In a precious report, epidermal growth factor receptor (EGFR) mutation positive status may lead to resistance to durvalumab [2]. The primary objective of this study was to validate whether patients who received durvalumab > 6 months after dCRT for LA-NSCLC show better survivals than those who did not, and to investigate whether EGFR and programmed death ligand 1 (PD-L1) status influenced outcomes in the Asian population in a real-world setting. Material/Methods: A total of 56 patients who received dCRT for stage III NSCLC were retrospectively analysed. Progression-free survival (PFS) and overall survival (OS) were assessed according to the number of consolidation durvalumab cycles by landmark analysis at six months after completion of dCRT. Results: Consolidation durvalumab was administered in 48 patients (85.7%). Patients who received ≥ 20 cycles of durvalumab had significantly better PFS and OS than those who received < 20 cycles of durvalumab (Figure 1A and B). For the landmark analysis, 38 patients were analysed, excluding those who developed disease progression within six months after dCRT. Patients who received more courses of durvalumab tended to have better PFS and OS (Figure 1C and D). However, there were no significant differences in PFS and OS between patients who received ≥ 20 and 13–19 cycles of durvalumab (p = 0.383 and 0.193, respectively).